CCL

Összesen 19 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM005896
Első szerző:Bajnok László (belgyógyász)
Cím:Relationship of serum resistin level of traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index / Bajnok L., Seres I., Varga Zs., Jeges S., Peti A., Karányi Zs., Juhász A., Csongrádi É., Mezősi E., Nagy E. V., Paragh Gy.
Dátum:2008
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and Clinical Endocrinology and Diabetes. - 116 : 10 (2008), p. 592-599. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Varga Zsuzsa (1951-) (biokémikus, nephrológus) Jeges Sára Peti Attila Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Juhász Attila (1970-) (szakorvos, klinikai mikrobiológus) Csongrádi Éva (1969-) (szakorvos) Mezősi Emese Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász)
Internet cím:elektronikus változat
DOI
Borító:

2.

001-es BibID:BIBFORM073014
Első szerző:Berta Eszter (belgyógyász)
Cím:Early stage Graves' disease is uniformly accompanied by orbital immune activity even in patients who fail to develop orbithopathy during follow-up / Eszter Berta, Miklós Bodor, László Galuska, György Paragh, Annamária Erdei, Annamária Gazdag, Bernadett Ujhelyi, Ervin Berényi, Mónika Katkó, Andrea Gazsó, Endre V. Nagy
Dátum:2018
ISSN:0947-7349
Megjegyzések:Purpose. Graves' orbitopathy (GO) is a complication of Graves' disease (GD), the development of which cannot be predicted at the time of diagnosis of GD. Our aims were (i) to test if orbital 99mTc-labelled diethylenetriamine pentaacetic acid single-photon emission computer tomography (DTPA SPECT) can predict development of GO later during the course of the disease and (ii) to study whether orbital immune activity can be detected in GD patients who do not develop GO during follow-up.Methods. Fifty-four orbits of 27 patients with newly diagnosed GD were entered into the case-control study. Individuals showing signs of GO at enrolment were excluded. During the two-year follow up, eye signs were recorded every 3 months. Orbital DTPA uptakes on SPECT images were measured when entering the study and at the end of the follow-up period, or when clinical signs of GO developed, whichever occurred first.Results. During thefollow up, 6 patients (22%) were diagnosed with GO. There was no significant difference between the initial DTPA uptakes of the patients with or without later developing GO (10.45?1.72 MBq/cm vs. 9.18?1.18 MBq/cm3 respectively). However, the DTPA uptakes of both GD groups (ie. with and without GO) were higher than that of the control group (7.45?1.36 MBq/cm3, p<0.05).Conclusions. We have shown that GD is accompanied by moderate orbital immune activity in GD patients without GO, irrespective of later development of GO. Why this orbital autoimmunity remains subclinical in the majority of the cases, and progresses into clinically detectable GO in others, remains unclear.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
pajzsmirigy
endokrin orbitopathia
Megjelenés:Experimental And Clinical Endocrinology & Diabetes. - 126 : 10 (2018), p. 628-631. -
További szerzők:Bodor Miklós (1969-) (belgyógyász, endokrinológus) Galuska László (1946-) (belgyógyász, izotópdiagnoszta) Paragh György (1953-) (belgyógyász) Erdei Annamária (1976-) (belgyógyász) Gazdag Annamária (1979-) (belgyógyász) Ujhelyi Bernadett (1981-) (szemész) Berényi Ervin (1964-) (radiológus) Katkó Mónika (1980-) (biológus) Gazsó Andrea Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM041177
Első szerző:Burch, Henry B.
Cím:Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy / Burch, H. B., Sellitti, D., Barnes, S. G., Nagy, E. V., Bahn, R. S., Burman, K. D.
Dátum:1994
ISSN:0021-972X
Megjegyzések:Autoimmunity against the TSH receptor (hTSH-R) is known to be the proximate cause of thyroidal activation in Graves' disease, but has not been definitively linked to extrathyroidal manifestations of this disorder, such as ophthalmopathy and pretibial myxedema. In an effort to increase our knowledge concerning mechanisms responsible for Graves' ophthalmopathy, we used antiserum directed against a highly immunogenic portion of the hTSH-R (amino acids 352-367; P1) to assess the presence of this receptor or immunologically related protein in cultured human retroocular fibroblasts obtained from patients with Graves' ophthalmopathy. Immunoenzymatic and immunofluorescent studies revealed specific staining of both cytoplasmic and cell membrane-associated protein in discrete vesicles. To further evaluate the immunoreactive species present in these cells, immunoblotting experiments were performed using hTSH-R-specific antisera (anti-P1) and sera obtained from patients with Graves' disease. Several protein bands were identified using both anti-P1 and Graves' disease patient sera, including species at mol wt of 95, 71, and 18 kilodaltons, the possible significance of which is discussed. The results support the hypothesis that immunity against the hTSH-R or related proteins contributes to the ophthalmopathy of Graves' disease.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Clinical Endocrinology & Metabolism. - 78 : 6 (1994), p. 1384-1391. -
További szerzők:Sellitti, D. Barnes, Stephen Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Bahn, R. S. Burman, Kenneth D.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM126872
035-os BibID:(WoS)001395884300001
Első szerző:Galgóczi Erika (biológus)
Cím:Stimulation of Piezo1 Mechanosensitive Channels Inhibits Adipogenesis in Thyroid Eye Disease / Galgoczi Erika, Orsos Istvan, Molnar Zsanett, Ujhelyi Bernadett, Steiber Zita, Szabo Laszlo, Dienes Beatrix, Csernoch Laszlo, Nagy Endre V, Katko Monika
Dátum:2025
ISSN:0021-972X
Megjegyzések:Context: Increased orbital tissue volume due to matrix expansion, orbital fibroblast (OF) proliferation, and adipocyte differentiation are the hallmarks of thyroid eye disease (TED). Their combination with the presence of hyaluronan-bound excess water in the constrains of the bony orbit results in increased intraorbital pressure. High intraorbital pressure, along with changes in the mechanical properties of orbital tissues, may lead to the activation of mechanosensitive receptors. The expression and role of the Piezo1 mechanoreceptor has not been investigated in TED. Objective: We aimed to verify the expression of Piezo1 in OFs, and to study the effect of in vitro Piezo1 activation by its synthetic agonist Yoda1 on adipocyte differentiation. Methods: OF cultures established using orbital connective tissues from patients with TED and controls were studied in the presence or absence of adipogenic stimuli. Piezo1 expression was confirmed by Western Blot and immunofluorescent imaging, and its function was verified by intracellular Ca2+ measurement. Adipogenic differentiation was characterized using Oil Red O staining for lipid accumulation, real-time polymerase chain reaction for gene and Western blot for protein expressions indicative in adipogenesis. Results: OFs express functional Piezo1 channels. Differentiation into adipocytes is inherent to TED OFs. Piezo1 activation by Yoda1 inhibits the expressions of early (CEBP?, CEBP?) and main (PPAR?, CEBP?) transcription factors, and the terminal marker FABP4 during adipogenesis, resulting in markedly lower intracytoplasmic lipid accumulation. Conclusion: Piezo1 channels are expressed and functional in OFs. Modeling orbital pressure by in vitro Piezo1 activation reduces de novo adipogenesis of OFs derived from TED orbits.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
orbital fibroblasts
adipogenesis
Piezo1
Yoda1
PPAR gamma
Graves orbitopathy
Megjelenés:Journal Of Clinical Endocrinology & Metabolism. - 110 : 9 (2025), p. 2584-2594. -
További szerzők:Orsós István (1999-) (molekuláris biológus) Molnár Zsanett (1982-) (analitikus) Ujhelyi Bernadett (1981-) (szemész) Steiber Zita (1977-) (orvos, szemész) Szabó László (1994-) (molekuláris biológus) Dienes Beatrix (1972-) (élettanász, molekuláris biológus) Csernoch László (1961-) (élettanász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Katkó Mónika (1980-) (biológus)
Pályázati támogatás:OTKA-143464
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM131919
035-os BibID:(scopus)105012975499 (wos)001548867600001
Első szerző:Galofré, Juan C.
Cím:Thyroid Hormone Treatment for Hypercholesterolemia in Euthyroid Patients : Results From a European Survey of Thyroid Specialists / Galofré Juan C., Díez Juan J., Attanasio Roberto, Nagy Endre V., Bednarczuk Tomasz, Papini Enrico, Zarkovic Milos, Negro Roberto, Perros Petros, Akarsu Ersin, Alevizaki Maria, Ayvaz Göksun, Berta Eszter, Beleslin Biljana Nedeljkovic, Bodor Miklos, Borissova Anna Maria, Boyanov Mihail, Burlacu Maria-Cristina, Ciric Jasmina, Fadeyev Valentin, Field Benjamin C. T., Fuhrer Dagmar, Jan Jiskra, Kopp Peter, Krebs Michael, Krsek Michal, Lazúrová Ivica, Luchytskiy Vitaliy, Puga Francisca Marques, McGowan Anne, Metso Saara, Moran Carla, Morgunova Tatyana, Niculescu Dan Alexandru, Peric Bozidar, Planck Tereza, Robenshtok Eyal, Rosselet Patrick Olivier, Ruchala Marek, Shepelkevich Alla, Tronko Mykola, Unuane David, Vardarli Irfan, Visser W. Edward, Vryonidou Andromachi, Younes Younes R., Hegedüs Laszlo
Dátum:2025
ISSN:0300-0664
Megjegyzések:Objective: A relationship among hypothyroidism and lipid disorders is well established. However, current evidence and guidelines donot support the use of thyroid hormones (TH) in euthyroid patients with hyperlipidaemia as potential harms are considerable. ThisEuropean survey investigated the use of TH in euthyroid patients with severe hypercholesterolemia as a complementary treatment.Design: Data were derived from the THESIS (Treatment of Hypothyroidism in Europe by Specialists) project that surveyed THuse. Univariable and multivariable analyses were used to explore associations.Results: Out of 17,232 invitations, 5695 (33.0%) valid responses were received, and of these, 328 (5.8%) stated that TH areindicated in euthyroid patients with severe hypercholesterolemia. Univariable analyses disclosed significant differences andassociations: (a) more non?endocrinologists (8.9%) than endocrinologist (5.4%) used TH (p < 0.001), (b) the number of hypothyroidpatients treated per year was inversely related to use of TH (p = 0.024), (c) members of international endocrine/thyroid societieswere more likely to use TH than non?members (p < 0.001), (d) significant variations by country and geographical region(p < 0.001), and (e) inverse relationship between gross national income per capita (GNIPC) and TH use (p < 0.001). Multivariableanalyses yielded significant associations between use of TH, and male gender, specialty and GNIPC (p < 0.001).Conclusions: This study suggests that a small but noteworthy minority of European thyroid specialists may be using TH to treatof severe hypercholesterolemia in euthyroid patients. If confirmed, this finding highlights the importance of raising awarenessamong thyroid specialists, professional societies, and healthcare providers to ensure adherence to evidence?based practices.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
euthyroidism
hypercholesterolemia
levothyroxine
misuse
treatment
Megjelenés:Clinical Endocrinology. - 2025 (2025), p. 1-8. -
További szerzők:Díez, Juan J. Attanasio, Roberto Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Bednarczuk, Tomasz Papini, Enrico Zarkovic, Milos Negro, Roberto Perros, Petros Akarsu, Ersin Alevizaki, Maria Ayvaz, Goksun Berta Eszter (1980-) (belgyógyász) Beleslin, Biljana Nedeljkovic Bodor Miklós (1969-) (belgyógyász, endokrinológus) Borissova, Anna-Maria I. Boyanov, Mihail A. Burlacu, Maria-Cristina Ciric, Jasmina Fadeyev, Valentin Field, Benjamin C. T. Fuhrer, Dagmar Jan, Jiskra Kopp, Peter Krebs, Michael Krsek, Michal Lazúrová, Ivica Luchytskiy, Vitaliy Puga, Francisca Marques McGowan, Anne Metso, Saara Moran, Carla Morgunova, Tatyana Niculescu, Dan Alexandru Peric, Bozidar Planck, Tereza Robenshtok, Eyal Rosselet, Patrick Ruchaa, Marek Shepelkevich, Alla P. Tronko, Mykola D. Unuane, David Vardarli, Irfan Visser, W. Edward Vryonidou, Andromachi Younes, Younes Ramazan Hegedüs László
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM017859
Első szerző:Gazdag Annamária (belgyógyász)
Cím:Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-t4 therapy / Gazdag A., Nagy E. V., Burman K. D., Paragh Gy., Jenei Z.
Dátum:2010
Megjegyzések:We aimed to compare the changes of endothelial function and haemostatic, inflammatory and metabolic parameters of short-term iatrogenic hypothyroidism to the characteristics of subclinical hyperthyroidism in patients with differentiated thyroid cancer. DESIGN: Twenty four women (mean age 42.4+/-8.1 years) had undergone total thyroidectomy and radioiodine ablation in treatment for differentiated thyroid cancer. We measured serum thyroglobulin, thyroid function, plasma levels of lipid parameters, homocystine, C-reactive protein, fibrinogen, von Willebrandt factor activity (vWF), nitric oxide, as well as flow-mediated vasodilatation (FMD) and nitroglycerin-mediated vasodilatation of the brachial artery during iatrogenic hypothyroidism (TSH 89.82+/-29.36 mU/L) and again in the same patients during subclinical hyperthyroidism secondary to exogenous levothyroxine administration (TSH 0.24+/-0.11 mU/L). RESULTS: In hypothyroidism, FMD was markedly lower than in subclinical hyperthyroidism (6.79+/-4.44 vs. 14.37+/-8.33%, p<0.005). Total cholesterol (7.34+/-1.23 vs. 4.75+/-1.14 mmol/L, p<0.001), LDL-cholesterol (4.55+/-1.10 vs. 2.70+/-0.89 mmol/L, p<0.005) and homocystine (12.95+/-4.49 vs. 9.62+/-2.29 micromol/L, p<0.005) were significantly higher in hypothyroidism. There was no difference in nitroglycerin-mediated vasodilatation, blood pressure, serum triglyceride and HDL-cholesterol levels according to thyroid function. Fibrinogen (3.23+/-0.50 vs. 4.01+/-0.84 g/L, p<0.005), vWF (90.09+/-25.92 vs.130.63+/-29.97%, p<0.001), C-reactive protein (4.39+/-5.16 vs. 5.55+/-5.15 mg/L, p<0.001) and plasma nitric oxide (24.56+/-6.71 vs. 32.34+/-7.0 micromol/L, <0.005) values were significantly lower in hypothyroidism. FMD correlated in a positive manner with fibrinogen, vWF and nitrogen oxide. CONCLUSIONS: Chronic subclinical hyperthyroidism was associated with improved endothelial function and lipid profile, while haemostatic and inflammatory parameters were impaired. The two opposite mechanisms may well compensate for each other at the level of the vessel wall.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and Clinical Endocrinology & Diabetes 118 : 6 (2010), p. 381-387. -
További szerzők:Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Burman, Kenneth D. Paragh György (1953-) (belgyógyász) Jenei Zoltán (1968-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM033124
035-os BibID:PMID:16025395
Első szerző:Győry Ferenc (kardiológus)
Cím:Establishment of the hu-PBL-SCID mouse model for the investigation of thyroid cancer / F. Győry, E. Mezősi, Sz. Szakáll, L. Bajnok, E. Varga, A. Borbély, A. Gazdag, I. Juhász, G. Lukács, E. V. Nagy
Dátum:2005
Megjegyzések:New experimental models of human neoplastic diseases attempt to mimic the human environment that fostered the development of disease in cancer patients. The aim of the present study was to establish a human lymphocyte-engrafted, severe combined immunodeficient (hu-PBL-SCID) mouse model to investigate thyroid cancer and to evaluate the potential use of this model for cancer immunotherapy. Thyroid neoplastic tissues were obtained from ten patients (one follicular adenoma, five papillary, one follicular, one anaplastic and two medullary cancers). One 8 x 4 x 3 millimeter sample from each tumor was cut into two pieces of identical size and transplanted into two SCID mice. In each case, one of the two mice was injected intraperitoneally with lymphocytes from the same tumor patient for the reconstitution of the human immune system (Group A), while the other animal received no lymphocytes (Group B). The engraftment of the tumors was successful in all cases. The growth rate was highly dependent on the histological type. When histologies were compared before implantation and after the removal of the implants, the characters of the tumors proved to be unchanged, except one case where an anaplastic cancer arose from a papillary tumor. Macrophages were present in all but one papillary cancer. All differentiated thyroid cancers were infiltrated by T and B lymphocytes. Lymphocytes and macrophages disappeared from 19/20 grafts by week 16. However, in one case from group A lymphocytes were detected four months after the transplantation. In another case from group A, one papillary cancer spontaneously decreased in size and disappeared. Before implantation, HLA-DR expression was detected in every papillary cancer. HLA-DR expression in the grafts was not seen in 3/5 cases by week 16. In conclusion, an animal model has been established for the investigation of human thyroid cancer, by which the analysis of anti-tumor immunity, as a postulate of immune therapy, may be possible.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Experimental and clinical endocrinology and diabetes 113 : 7 (2005), p. 359-364. -
További szerzők:Mezősi Emese Szakáll Szabolcs (1970-) jr. Bajnok László (1961-) (belgyógyász) Varga E. Borbély A. Gazdag Annamária (1979-) (belgyógyász) Juhász István (1956-) (bőrgyógyász, bőrsebész, kozmetológus, klinikai onkológus) Lukács Géza (1941-) (sebész) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

8.

001-es BibID:BIBFORM072318
Első szerző:Kocsis Judit (onkológus)
Cím:First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer : efficacy and Safety Analysis / Judit Kocsis, Éva Szekanecz, Ali Bassam, Andrea Uhlyarik, Zsuzsanna Pápai, Gábor Rubovszky, Emese Mezősi, Károly Rucz, Ildikó Garai, Endre Nagy, Iván Uray, Zsolt Horváth
Dátum:2019
Megjegyzések:Background Medullary thyroid cancer (MTC) is a rare disease,the prognosis of advanced and metastatic disease is poor andfew therapeutic options are available in this setting. Based onthe results of phase II and III studies with sorafenib in differentiatedthyroid cancer and the lack of availability of registeredtyrosine kinase inhibitors, vandetabin and cabozantinib in Hungary,we designed a uncontrolled, prospective efficacy andsafety study of patients with metastatic MTC treated with firstlinesorafenib in five Hungarian oncology centers.Methods Ten consecutive patients with progressive or symptomaticmetastatic MTC were included and started sorafenib400 mg twice a day between June 2012 and March 2016. Theprimary end point was median progression-free survival(mPFS). Secondary endpoints included disease control rate,biochemical response, symptomatic response and toxicity.Results Four patients achieved partial remission (40 %) accordingto RECIST 1.1 evaluation. Five patients had stable diseasebeyond 12 months (50 %) and one patient had progressivedisease (10 %). Median PFS was 19.1 months. The disease controlrate was 90 %. Association between radiologic responseand biochemical or symptomatic response was inconsistent.Most common side effects were Grade 1-2 fatigue (60 %),palmar-plantar erythrodysesthesia, rash/dermatitis 50-50 %,alopecia 40 %.Conclusions In our prospective case series in patients withMTC first-line sorafenib showed at least similar efficacy as inother small phase II trials and case reports. Based on comparableefficacy with registered tyrosine kinase inhibitors and it'smanageable toxicity profile, we believe that sorafenib has rolein the sequential treatment of MTC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and clinical endocrinology & diabetes. - 127 : 4 (2019), p. 240-246. -
További szerzők:Szekanecz Éva (1968-) (onkológus szakorvos) Bassam, Ali Uhlyarik Andrea Pápai Zsuzsanna Rubovszky Gábor Mezősi Emese Rucz Károly (1962-) Garai Ildikó (1966-) (radiológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Uray Iván Péter (1970-) (kutatóorvos) Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM063083
Első szerző:Lábadi Árpád
Cím:Loss-of-Function Variants in a Hungarian Cohort Reveal Structural Insights on TSH Receptor Maturation and Signaling / Lábadi Árpád, Grassi, Elisa Stellaria, Gellén Balázs, Kleinau Gunnar, Biebermann Heike, Ruzsa Beáta, Gelmini, Giulia, Rideg Orsolya, Miseta Attila, Kovács Gábor L., Patócs Attila, Felszeghy Enikő, Nagy Endre V., Mezősi Emese, Persani, Luca
Dátum:2015
ISSN:0021-972X
Megjegyzések:CONTEXT:Congenital hypothyroidism (CH) is one of the most common inborn endocrine disorders with genetic background. Despite the well-established newborn CH screening program in Hungary, no systematic examination of the underlying genetic alterations has been performed as yet.OBJECTIVE:We aimed to explore TSH receptor (TSHR) mutations in a cohort of Hungarian patients with CH.PATIENTS:Eighty-five unrelated patients with permanent primary CH, all diagnosed at newborn screening, were selected.MAIN OUTCOME MEASURES:Coding exons of the TSHR gene were sequenced and evaluated together with the thyroid-specific clinical parameters. Functional features of the novel mutations were experimentally examined, and their comparative molecular models were built.RESULTS:In four patients (one heterozygous and three compound heterozygous), seven TSHR mutations were identified. Among these, N432(1.50)D and P449(2.39)L are novel missense alterations. Importantly, the N432(1.50) residue is highly conserved among G protein-coupled receptors, and its function has not been examined yet in human glycoprotein hormone receptors. Our results indicate that the N432(1.50)D mutation disrupts important, architecture-stabilizing intramolecular interactions and ultimately leads to the complete intracellular retention of the receptor. On the other hand, P449(2.39) is located in the intracellular part of the receptor, which is important in G protein coupling. The P449(2.39)L mutation results in signaling impairment, with a more profound effect on the Gq/11 pathway.CONCLUSION:TSHR mutations are common among Hungarian patients with CH. The novel genetic alterations revealed an important structural role of the N432(1.50) and the P449(2.39) residues in receptor expression and signaling, respectively.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Congenital hypothyroidism
TSH receptor
newborn CH screening program
Megjelenés:Journal Of Clinical Endocrinology & Metabolism. - 100 : 7 (2015), p. E1039-E1045. -
További szerzők:Grassi, Elisa Stellaria Gellén Balázs Kleinau, Gunnar Biebermann, Heike Ruzsa Beáta Gelmini, Giulia Rideg Orsolya Miseta Attila Kovács Gábor L. (Szeged) Patócs Attila Felszeghy Enikő Noémi (1970-) (gyermekgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Mezősi Emese Persani, Luca
Pályázati támogatás:RF-2010-2309484
Egyéb
KL2334/2-2
Egyéb
BI 893/6-3
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM121622
035-os BibID:(Scopus)85187478569 (WoS)001181730800001
Első szerző:Lafontaine, Nicole
Cím:Use of thyroid hormones in hypothyroid and euthyroid patients : a survey of members of the Endocrine Society of Australia / Nicole Lafontaine, Suzanne J. Brown, Petros Perros, Enrico Papini, Endre V. Nagy, Roberto Attanasio, Laszlo Hegedüs, John P. Walsh
Dátum:2024
ISSN:0300-0664
Megjegyzések:Objective: Hypothyroidism is a common endocrine condition usually managed with levothyroxine (LT4). However, controversy remains around the use of liothyronine (LT3). We aimed to investigate the practices of Australian endocrinologists when managing patients with hypothyroidism, their use of LT3 + LT4 combination therapy and use of thyroid hormones in euthyroid patients. Design and Participants: Members of the Endocrine Society of Australia (ESA) were invited to participate in an online questionnaire. Measurements: We analysed questionnaires that had complete demographic data. Results: Eighty-seven questionnaires fulfilled the criteria. LT4 was used as first line treatment for hypothyroidism by all respondents. Only 45% reported that their patients were dispensed the brand of LT4 that they recommend. LT3 (alone or in combination) was prescribed by 44% in their clinical practice. Although 49% of respondents would consider LT3 + LT4 in patients with normal TSH who had ongoing symptoms of hypothyroidism, the inability of LT4 to restore normal physiology was ranked the least likely explanation for persistent symptoms and only 32% would consider it for themselves if they were diagnosed with hypothyroidism. The majority (55%), in accordance with evidence, would not prescribe thyroid hormone to euthyroid individuals but 39% would consider use in euthyroid female infertility with high levels of thyroid antibodies and 11% in euthyroid patients with a simple goitre growing over time. LT4 use in pregnancy was variable among members. Conclusions: Australian endocrinologists mostly follow international guidelines when prescribing thyroid hormone therapy and many prescribe combination LT3 and LT4 therapy, particularly for patients who remain symptomatic on LT4 monotherapy. Prescribing practices are largely similar to other countries who have completed similar questionnaires.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Australia
endocrinologist
hypothyroidism
thyroxine
triiodothyronine
Megjelenés:Clinical Endocrinology. - 100 : 5 (2024), p. 477-485. -
További szerzők:Brown, Suzanne J. Perros, Petros Papini, Enrico Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Attanasio, Roberto Hegedüs László Walsh, John P.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM041175
Első szerző:Leövey András (belgyógyász)
Cím:Lymphocytes resided in the thyroid are the main source of TSH-receptor antibodies in Basedow's-Graves' disease? / Leövey A., Nagy E., Balázs G., Bakó G.
Dátum:1992
ISSN:0232-7384
Megjegyzések:The source of TSH-receptor antibodies (TRAb) in Basedow's-Graves' disease is still under debate. Previous studies by other groups had found TRAb levels in the thyroid vein higher than or equal to that in the peripheral vein. The aim of the present work was to investigate the suspected presence of this TRAb gradient in 14 Graves' patients who underwent surgery. Interestingly, in 6 patients higher levels of TRAb were measured in the antecubital vein when compared to the thyroid vein, in another 6 there was no gradient and 2 exhibited higher TRAb levels in their thyroid veins. A clear gradient of thyroid hormones in favour of the thyroid vein was also present, while no gradient of TSH, anti-thyreoglobulin and anti-microsomal antibodies, total IgG, IgA and IgM levels and no differences of the CD4+/CD8+ cell ratios were found between the two sampling sites. We conclude that cells other than lymphocytes residing in the thyroid gland must also be involved in TRAb production.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental And Clinical Endocrinology. - 99 : 3 (1992), p. 147-150. -
További szerzők:Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Balázs György (1933-) (sebész) Bakó Gyula (1951-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM135452
035-os BibID:(scopus)105012857276 (wos)001546431600001
Első szerző:Liu, Anna
Cím:Canadian Endocrinologists' Perspectives on Treatment With Thyroid Hormone Substitutions in Euthyroid and Hypothyroid Patients : a 2023 THESIS Questionnaire Survey / Liu Anna, Morrison Deric, Hegedüs Laszlo, Nagy Endre V., Papini Enrico, Perros Petros, Attanasio Roberto, Negro Roberto, Van Uum Stan, Nygaard Birte, Bonnema Steen J., Riis Kamilla R.
Dátum:2025
ISSN:0300-0664
Megjegyzések:Objective: The practice of treating hypothyroid and euthyroid patients with thyroid hormones varies between countries, as observed in the recent surveys of European thyroid experts, THESIS. As part of the THESIS initiative, we investigated Canadian endocrinologists' perspectives on this topic, focusing on combination therapy with either liothyronine (LT3) plus levothyroxine (LT4) or desiccated thyroid extract (DTE). Design: Members of the Canadian Society of Endocrinology and Metabolism (CSEM) were invited to participate in an anonymous online survey. Results: Out of 348 eligible CSEM members, 68 (19.5%) respondents were included in the analysis. All respondents used LT4 as the first-line treatment for hypothyroid patients. Many respondents (64.7%) would consider LT4 + LT3 for patients on LT4 with persistent symptoms, whereas fewer would consider DTE (16.2%). Most respondents attributed persistent symptoms in LT4-treated patients to psychosocial factors, comorbidities, or unrealistic expectations. Approximately half of the respondents stated that thyroid hormone therapy is never indicated for euthyroid patients. The remaining respondents considered thyroid hormones for euthyroid women with infertility and high thyroid antibody levels (36.8%), depression (13.2%), and growing goiter (7.4%). Conclusions: Following current guidelines, LT4 tablet is the preferred treatment for hypothyroidism. Most respondents would consider triiodothyronine-containing therapy for patients with persistent symptoms, preferring LT4 + LT3 over DTE. The number of endocrinologists considering combination therapy for hypothyroid patients in Canada was higher than in Europe. Finally, at variance with current guidelines, a fraction of the respondents would consider thyroid hormones in patients with non-thyroidal conditions.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmunity
Canadian Society of Endocrinology and Metabolism
Desiccated thyroid extract
Hypothyroidism
Levothyroxine
Liothyronine
Questionnaire
Megjelenés:Clinical Endocrinology. - 103 : 5 (2025), p. 739-748. -
További szerzők:Morrison, Deric Hegedüs László Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Papini, Enrico Perros, Petros Attanasio, Roberto Negro, Roberto Van Uum, Stan Nygaard, Birte Bonnema, Steen Joop Riis, Kamilla Ryom
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.